HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced NSCLC: Results From a Multicenter Phase 2 Study 🎙️Dr. Shaodong Hong 🔢2631RO 🎯Overall: ORR 57.9%, DCR 89.5%, 6-Mo PFS 64.8% 🎯ORR 83% in PD-L1 TPS≥50% 🎯Grade≥3 Stomatitis Only 7.2%, Grade≥3 TRAEs 38.1% ☑️NCT06341114 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT06341114NCT06341114按 - **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors 对上
- **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com